Downloads provided by UsageCounts
En este artículo (carta al director), se pone en valor el hecho de que, de forma pionera, un apósito de nombre comercial Urgostart® (Urgo Medical), ha sido reconocido a principios de 2019 por la NICE, atribuyéndole evidencia concluyente para tratar úlceras venosas de las piernas y úlceras de pie diabético. No es la primera vez que la NICE hace evaluación de apósitos para determinar la evidencia en la prevención o tratamiento de diferentes úlceras o heridas crónicas; pero hasta la fecha, todas ellas habían concluido sin poder determinar dicha evidencia de forma definitiva. Las conclusiones de la NICE sobre UrgoStart se resumen en las siguientes recomendaciones: a) Hay evidencia para usar los apósitos UrgoStart como primera opción para tratar las úlceras del pie diabético y úlceras venosas de la pierna (cuando no hay infección) y b) Existe evidencia del uso de UrgoStart para tratar las úlceras del pie diabético, con un ahorro de costes de £ 342 (401,40€) por paciente/año y evidencia no concluyente en el caso de úlceras venosas en la pierna. [New evidence for the treatment of venous leg ulcers and diabetic foot] Abstract: In this article (letter to the director), the fact that, in a pioneering way, a dressing of commercial name Urgostart® (Urgo Medical), has been recognized at the beginning of 2019 by the NICE, attributing conclusive evidence to treat venous leg ulcers and diabetic foot ulcers. It is not the first time that NICE has evaluated dressings to determine the evidence in the prevention or treatment of different ulcers or chronic wounds; but to date, all of them had concluded without being able to determine that evidence definitively. The NICE conclusions on UrgoStart are summarized in the following recommendations: (a) There is evidence to use UrgoStart dressings as the first option to treat diabetic foot ulcers and venous leg ulcers (when there is no infection) and (b) There is evidence of use of UrgoStart to treat diabetic foot ulcers, with a cost savings of £ 342 (€ 401,40) per patient / year and inconclusive evidence in the case of venous leg ulcers.
NICE, UrgoStart, venous leg ulcers, diabetic foot
NICE, UrgoStart, venous leg ulcers, diabetic foot
| selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | 0 | |
| popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network. | Average | |
| influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | Average | |
| impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network. | Average |
| views | 7 | |
| downloads | 9 |

Views provided by UsageCounts
Downloads provided by UsageCounts